ABILIFY Now Applicable to Maintenance Treatment of Bipolar Disorder: FDA Approves New Indication
Main Category: BipolarArticle Date: 13 Mar 2005 - 12:00 PDT
email to a friend 
printer friendly 
opinions
| Patient / Public: |  | |
| Healthcare Prof: | |
Tokyo (JCNN) - Bristrol-Myers Squibb (BMS) and Otsuka Pharmaceutical have jointly announced that the US Food and Drug Administration (FDA) approved an additional indication for ABILIFY (aripiprazole) Tablets and Oral Solution, atypical antipsychotics, as of March 1.
With this approval, ABILIFY is now applicable to the maintenance treatment, namely preventing relapses, of bipolar I disorder. Since its initial approval in 2002, over 3.7 million prescriptions have been written in the US.
In Japan, ABILIFY , for which a new drug application was filed in March 2003, is currently under examination.
View Otsuka Pharmaceutical Co., Ltd. company profile here
Copyright © 2001-2004 JCNN. All rights reserved. A division of Japan Corporate News Network KK.
Visit our bipolar section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/21156.php>
APA
http://www.medicalnewstoday.com/releases/21156.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Privacy Policy |
Terms and Conditions
MediLexicon International Ltd
Bexhill-on-Sea, United Kingdom
MediLexicon International Ltd © 2004-2012 All rights reserved.
